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One Sentence Summary: IL-36 receptor (IL36R) blockade ameliorates psoriatic inflammation 
and should be well tolerated, since IL36R knockout mutations are benign.  
 
Abstract: Interleukin (IL)-36, - and – are innate mediators of acute epithelial inflammation. 
Here we sought to demonstrate that these cytokines are also required for the pathogenesis of 
plaque psoriasis, a common and chronic skin disorder, caused by abnormal TH17 cell activation. 
To investigate this possibility, we first defined the genes that are induced by IL-36 cytokines in 
primary human keratinocytes. This enabled us to demonstrate a significant IL-36 signature 
among the transcripts that are up-regulated in plaque psoriasis and the susceptibility loci 
associated with the disease in genome-wide studies. Next, we investigated the impact of in-vivo 
and ex-vivo IL-36 receptor blockade using a neutralizing antibody or a recombinant antagonist. 
Both inhibitors had marked anti-inflammatory effects on psoriatic skin, demonstrated by 
statistically significant reductions in IL-17 expression, keratinocyte activation and leukocyte 
infiltration. Finally, we explored the potential safety profile associated with IL-36 blockade by 
phenotyping twelve individuals carrying knockout mutations of the IL-36 receptor gene. We 
found that normal immune function was broadly preserved in these individuals, suggesting that 
IL-36 signaling inhibition would not substantially compromise host defenses. These 
observations, which integrate the results of transcriptomics and model system analysis, pave the 
way for early-stage clinical trials of IL-36 antagonists. 
Introduction 
Interleukin (IL)-36, - and – are a group of IL-1 family cytokines that signal through a 
common dimeric receptor, composed of the IL-36R and IL-1RAcP subunits. The activation of 
this complex triggers Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-B) 
and Mitogen Activated Protein Kinase (MAPK) signaling, leading to the production of pro-
inflammatory molecules such as IL-1, IL-6 and IL-8 (1). Conversely, binding of IL-36R by 
the IL-36 receptor antagonist (IL-36Ra, encoded by the IL36RN gene) blocks downstream signal 
transduction (1). The importance of this immunomodulatory mechanism was underscored by the 
discovery of loss-of-function IL36RN mutations in patients with generalized pustular psoriasis 
(GPP) (2). This is a severe autoinflammatory disorder, which is characterized by recurrent 
episodes of neutrophilic skin pustulation and systemic inflammation (manifesting as an acute 
phase response with neutrophilia) (3). Of note, the majority of GPP patients also present with 
plaque psoriasis (hence psoriasis), a chronic and disfiguring skin disease that affects 1-3% of the 
population (3).  
Research carried out in the last decade has demonstrated that the abnormal activation of T 
helper 17 (TH17) lymphocytes is a major disease driver in psoriasis (4). At the same time, 
several lines of evidence suggest that IL-36 cytokines are also likely to have a pathogenic role. 
First, individuals with GPP show elevated IL-36 expression in skin (5) and present a risk of 
psoriasis that is ten times higher than that observed in the general population (6). Second, the 
gene encoding the IL-36 receptor (IL1RL2) maps to a locus showing genome-wide significant 
association with psoriasis (7). Finally, work carried out in animal models has demonstrated that 
IL-36 cytokines can activate dendritic cells and thus promote TH17 lymphocyte polarization (8). 
Since the IL-17 molecules released by TH17 cells can in turn up-regulate IL-36 production, it 
has been proposed that the two cytokines drive a powerful feedback loop, which effectively 
propagates skin inflammation (9).  
Taken together, the above observations suggest that germline IL36RN mutations cause 
widespread up-regulation of IL-36 signaling and severe autoinflammation (GPP), while 
localized, TH17-dependent over-expression of IL-36 cytokines amplifies cutaneous immune 
responses in psoriasis. Thus, we propose that IL-36 is a shared disease driver, which contributes 
to the onset of plaque and pustular psoriasis through different molecular mechanisms.    
Given that the role of IL-36 in GPP is well established, here we have investigated IL-36 
signaling as a pathogenic mediator and therapeutic target in psoriasis. By following-up the 
results of IL-36 transcription profiling with targeted inhibition experiments, we demonstrated 
that in-vivo and ex-vivo IL-36 blockade can reverse the inflammatory phenotype of psoriasis skin 
lesions. We also showed that mutations that abolish IL-36 signaling do not substantially 
compromise human immune function, suggesting that pharmacological IL-36 blockade is likely 
to have an acceptable safety profile.   
 
Results  
IL-36 signature genes are up-regulated in psoriatic skin lesions and enriched within psoriasis 
susceptibility loci 
To explore the role of IL-36 in psoriasis, we first assessed the presence of an IL-36 
signature in the disease transcriptome. To date, IL-36 target genes have only been profiled in a 
single microarray study, based on the stimulation of keratinocyte cultures with unprocessed IL-
36 cytokines (10). As these precursor molecules were later found to have minimal biological 
activity (11), the power to detect differential expression was limited. Here, we sought to generate 
a reference IL-36 transcriptome through the RNA sequencing of healthy primary keratinocytes 
treated with bio-active IL-36, - or - (table S1). The principal component analysis of our 
dataset demonstrated a complete separation between treated (n=3 for each cytokine) and 
untreated samples (n=3), but also an overlap between the profiles of keratinocytes stimulated 
with individual cytokines (Fig. 1A). This pattern was confirmed by unsupervised hierarchical 
clustering (Fig. 1B), suggesting important similarities between the three IL-36 transcriptomes. 
We found that 4096, 4459 and 3468 genes were differentially expressed (False Discovery 
Rate (FDR) <0.05) upon treatment with IL-36, IL-36 and IL-36 respectively (Fig. 1C). Of 
these, 207, 352 and 229 were up-regulated by at least two-fold (Fig. 1C, table S2). In keeping 
with the results of the principal component analysis and hierarchical clustering, we observed a 
substantial overlap between these datasets, as 182 genes (hereafter referred to as the IL36_182 
set) were induced by all three cytokines (Fig. 1C). These included previously described IL-36 
dependent loci (CCL20, CXCL1, IL8, DEFB4A, STEAP4) (5, 10), as well as novel targets such as 
the chemotactic proteins S100A7, S100A8, S100A9 and the phospholipase PLA2G4D, which 
generates the lipid antigens presented by Langerhans cells (12) (Fig. 1C, table S2).  
In keeping with the notion that IL-36 is a dominant cytokine in the GPP skin 
transcriptome, we found 58 IL36_182 genes among the 500 that were most significantly up-
regulated in a recently described (5)  GPP cohort   (Fig. 1D). We then re-analyzed a publicly 
available psoriasis dataset (13) and found 68 IL36_182 loci among the 500 most over-expressed 
genes (Fig. 1D). The overlap between the IL36_182 set and the genes up-regulated in psoriasis or 
GPP was highly significant (P<10-30 for both diseases), but the same did not apply to the gene set 
induced by IL-4 (P>0.03 for both GPP and psoriasis), a Th2 cytokine that was analyzed as a 
negative control (fig. S1). 
To complement the above observations, we also examined the overlap between IL-36 
target genes and psoriasis susceptibility intervals previously detected in genome-wide association 
studies (GWAS). We found that the IL36_182 set was significantly enriched among the genes 
that lie within psoriasis associated regions (P=9.1x10-4), but not among those that map to 
unrelated susceptibility loci, linked to autism or schizophrenia (P>0.05 for both diseases) (Fig. 
1E). Thus, our analyses identified a clear  IL-36 gene signature in GPP and psoriasis. 
 
IL-36 signature genes cluster to pathways implicated in the pathogenesis of psoriasis  
To further explore the biological significance of our differential expression findings, we 
undertook a gene set enrichment analysis of the IL-36, IL-36 and IL-36 transcriptomes. This 
demonstrated a marked over-representation of inflammatory processes implicated in the 
pathogenesis of psoriasis. In fact, the pathway showing the most significant enrichment in our 
dataset was Role of IL-17A in psoriasis, with FDR<10-10 observed for all three cytokines. In 
keeping with this result, a re-analysis of a published IL-17 transcriptome (14) revealed that 26/46 
(56%) of the genes that are up-regulated by IL-17 in keratinocytes are part of the IL36_182 set 
(table S3). 
Very significant FDRs were also detected for pathways related to the infiltration of 
inflammatory elements into lesional skin (Granulocyte adhesion and diapedesis and 
Agranulocyte adhesion and diapedesis; all FDR<10-6) and the activation of p38 MAPK signaling 
(FDR≤10-5) (Fig. 2A, table S4). Importantly, there was a marked overlap between the processes 
driven by IL-36, - and , with 45 pathways enriched in all three transcriptomes (P<10-30 for all 
pairwise comparisons) (Fig. 2B).  
We next extended our gene set enrichment analysis to the disease datasets. As expected, 
we found a substantial overlap between the pathways that were driven by IL-36 and those that 
were enriched in the GPP transcriptome (P= 9.4x10-31; fig. S2). We then examined the psoriasis 
dataset, where we identified 71 enriched pathways (FDR<0.05), 37 of which (52%) were shared 
with the IL-36 transcriptome (P=5.8x10-35) (Fig. 2C, table S4). In keeping with the results of the 
differential expression analysis, we found that the genes underlying these enrichment signals 
were all part of the IL36_182 set (table S4).  
To validate the effects of IL-36 cytokines on genes that are relevant to the pathogenesis 
of psoriasis, we stimulated keratinocyte cultures obtained from additional healthy donors (n=3). 
We focused our attention on a representative set of loci (highlighted in red font in Fig. 1C) that 
were markedly up-regulated in psoriatic skin and mapped to pathways that were enriched in the 
disease transcriptome. These included IL36G, S100A7 and LCN2 (Role of IL-17A signaling in 
psoriasis), CCL20, IL8 and MMP9 (Granulocyte/agranulocyte adhesion and diapedesis) as well 
as IRAK2 and PLA2G4D (p38 MAPK signaling). Real-time PCR analyses confirmed that these 
genes were all strongly up-regulated by IL-36, IL-36 and IL-36 (Fig. 3A). The induction was 
especially robust for S100A7 (all fold changes>50) and IL36G (fold changes>8.5). The latter 
result was also validated at the protein level (Fig. 3B) suggesting the presence of a feed-forward 
loop that sustains IL-36 expression in inflamed skin. , These results indicate that IL-36 cytokines 
(produced upon infection or trauma (fig. S3)) amplify keratinocyte inflammatory responses by 
up-regulating their own expression and that of molecules which attract TH17 cells (CCL20) and 
directly or indirectly potentiate IL-17 signaling (S100A7, LCN2, PLA2G4D) (fig. S4). 
 In-vivo IL-36 receptor blockade improves the phenotypic appearance of murine psoriasiform 
dermatitis  
Having demonstrated that IL-36 cytokines drive immune pathways that are critical to the 
pathogenesis of psoriasis, we proceeded to assess the anti-inflammatory effects of IL-36 
signaling inhibition. We first investigated the potential of IL-36 blockade in imiquimod-induced 
psoriasiform dermatitis, an IL17-mediated mouse model of the disease, which is widely used in 
preclinical studies (15, 16). As expected, we found that imiquimod administration resulted in an 
inflammatory skin phenotype characterized by increased acanthosis (epidermal thickness) (Fig. 
4, A and B), abundant leukocyte infiltration (Fig. 4, C and D), up-regulation of IL-17 producing 
T cells (Fig. 4E and fig. S5) and IL-17 mRNA (Fig. 4F). These pathological manifestations, 
however, were substantially mitigated by 48h pre-treatment with an anti-IL36R neutralizing 
antibody.  
First of all, the mice that had received the IL-36R blocking-antibody presented with less 
severe skin lesions compared to littermates treated with an IgG2a isotype control (Fig. 4A). IL-
36 inhibition was also associated with a ~30% reduction in acanthosis, which was accompanied 
by a comparable decrease in scale thickness (Fig. 4A). This was consistent with the observed up-
regulation of Krt10 (a marker of keratinocyte terminal differentiation) and the reduced 
expression of Krt16 (a marker of keratinocyte hyper-proliferation) (Fig. 4B).  
Secondly, flow cytometry analyses of skin cell suspensions demonstrated a substantial 
decrease in neutrophil infiltration in mice treated with the anti-IL36R antibody (Fig. 4C). These 
animals also showed a substantial decline in the numbers of  T cells (Fig. 4D), which was 
especially pronounced for the IL-17 producing sub-population (Fig. 4E). This decrease, which 
was mirrored by a reduced accumulation of IL-17+  T lymphocytes (fig. S5), was especially 
noteworthy, given the key pathogenic role of IL-17+  T cells in imiquimod-induced dermatitis 
(17).  
Finally, and in keeping with the diminished infiltration of inflammatory elements, real-
time PCR analysis of lesional skin showed reduced cytokine (Il36g, Il17a, Il22, Tnf, Csf2 and 
Csf3) and chemokine (Cxcl1, Cxcl2, Cxcl5) expression in mice treated with the anti-IL36R 
antibody (Fig. 4F). Taken together, these results show that in-vivo IL-36 signaling inhibition has 
powerful anti-inflammatory effects on psoriasiform dermatitis. 
 
Ex-vivo IL-36 receptor blockade improves the inflammatory phenotype of human psoriasis skin 
To further investigate the therapeutic potential of IL-36 blockade, we investigated a 
validated ex-vivo model of human psoriasis, based on the short-term culture (24h) of paired skin 
biopsies, obtained from lesional and non-lesional patient skin (18). This system reflects the 
complexity of the disease and effectively recapitulates the pathogenic cross-talk between 
keratinocytes and immune cells. Here, real-time PCR analysis of cultures obtained from 5 
independent patients confirmed the up-regulation of IL36G and IL17A in lesional skin (Fig. 5A). 
Importantly, supplementation of the culture medium with recombinant IL-36Ra markedly 
reduced the over-expression of these cytokines, alongside that of chemokines such as IL8 and 
CCL20 (Fig. 5A). The treatment also reduced the levels of KRT16, while increasing KRT10 
expression (Fig. 5A). Parallel ELISA measurements confirmed that IL-36Ra supplementation 
inhibited the release of IL-17 and IL-36 into the culture medium (Fig. 5B), thus validating the 
gene expression results at the protein level. 
Finally, immunofluorescence microscopy demonstrated a highly significant (albeit not 
absolute) reduction in the number of T lymphocytes and dendritic cells in IL-36Ra treated 
lesional skin (Fig. 5C). Given the decreased expression of chemokines such as CCL20, this is 
likely to reflect a reduced retention of immune cells within the tissue. 
To complement these findings, we sought to investigate the mechanisms underlying the 
effects of IL-36Ra on psoriatic lesions. We first examined the expression of the IL-36 receptor 
gene (IL1RL2) in disease relevant cell types. While transcript levels were low in normal skin-
resident T lymphocytes, in-vitro differentiated macrophages and in-vitro differentiated dendritic 
cells, IL1RL2 was very strongly expressed in keratinocytes (Fig. 5D). This suggests that IL-36Ra 
treatment mostly affects the latter cell type, where it inhibits IL-36R dependent chemokine and 
cytokine production. To further explore this model, we examined the impact of IL-36Ra on 
MAPK signaling, one of the main mediators of IL36-driven cytokine induction. We found that 
p38 phosphorylation, which was examined as a representative readout of MAPK activation, 
based on the results of pathway enrichment analysis, was markedly reduced in IL-36Ra treated 
skin (Fig. 5E). These experiments demonstrate that ex-vivo IL-36 inhibition reduces cytokine 
expression and leukocyte infiltration in psoriatic skin lesions, most likely through an effect on 
keratinocyte MAPK signaling.      
 
Phenotyping of individuals carrying IL1RL2 knockout mutations supports the safety of IL-36 
signaling blockade  
Having demonstrated the anti-inflammatory effects of IL-36 signaling inhibition in 
different experimental systems, we sought to establish whether pharmacological IL-36 blockade 
would compromise human immune function. We hypothesized that naturally occurring 
mutations in IL1RL2 (the gene encoding the IL-36 signaling receptor) would mimic the effects of 
IL-36 signaling blockade. We therefore proceeded to ascertain a sample of individuals with 
homozygous IL1RL2 loss-of-function alleles.  
To maximize the likelihood of identifying subjects carrying IL1RL2 knockout mutations, 
we focused our attention on a population displaying high rates of parental relatedness. We 
therefore queried the exome profiles of 2,162 unrelated British-Pakistani individuals recruited by 
Born in Bradford, a community based project which aims to investigate health outcomes in 
Bradford, UK (19). We found that 28 unrelated study participants (1.3%) harbored low-
frequency homozygous changes in IL1RL2. Twelve of these individuals carried likely knockout 
mutations, i.e. homozygous missense alleles classified as damaging by multiple algorithms (table 
S5). Of note, the most prevalent change was a p.Ala471Thr substitution, found in 9/12 subjects 
and previously characterized in-vitro as a deleterious allele (20). 
To investigate the impact of these damaging IL1RL2 changes on immune function, we 
first reviewed the medical records of the 12 individuals harboring damaging homozygous 
mutations. One had always lived in the United Kingdom, whereas the other 11 had grown up in 
rural Pakistan and only left the country as young adults. We found that all were in good health 
and none had suffered from cardiovascular disease, cancer or immune-mediated conditions. 
Importantly none of the 12 subjects had a history of recurrent infections. While IL-36 signaling 
has been implicated in host defense against M. tuberculosis (21), none of the 12 individuals had 
contracted tuberculosis, a condition that is endemic in Pakistan (22). All showed normal 
leukocyte counts (table S6).  
To further explore these findings, we recalled 6 subjects with deleterious IL1RL2 
mutations, 5 of whom were p.Ala471Thr homozygotes (the sixth was homozygous for a 
p.Ile229Met deleterious change). In parallel we also recruited 4 age- sex- and ethnicity matched 
controls, who carried wild-type IL1RL2 sequences (Fig. 6, A and B). Clinical examination 
confirmed that none of the individuals with IL1RL2 mutations presented with anomalies of the 
skin, oral mucosa or lymph nodes. Serology tests showed that total IgA, IgG and IgM levels 
were normal. The same applied to Aspergillus IgG levels, which were investigated as IL-36 
signaling has been implicated in the response to this particular pathogen (23). Finally, we found 
that all individuals with IL1RL2 mutations had circulating antibodies against varicella zoster 
virus and tetanus toxoid, showing that they had mounted an adequate immune response 
following antigen exposure (table S7).   
To investigate in more detail the immune phenotype associated with deleterious IL1RL2 
alleles, we obtained Peripheral Blood Mononuclear Cells (PBMCs) from the six individuals with 
homozygous knockout mutations and the four control subjects. We first demonstrated that 
IL1RL2 and IL1RAP (the gene encoding the IL-36R co-receptor) are both expressed in these cells 
(fig. S6). Next, we stimulated PBMCs with a representative IL-36 cytokine (IL-36). We found 
that this treatment failed to up-regulate downstream gene expression in the individuals with 
IL1RL2 knockout mutations (Fig. 6, C and D), despite a normal response to a control stimulation 
with phorbol myristate acetate (PMA)/ionomycin (Fig. 6E). This confirmed that the p.Ala471Thr 
and p.Ile229Met alleles abolish IL-36 receptor activity and formally demonstrated that the 
individuals who harbor these mutations lack a functional IL-36 receptor.  
Next, we treated PBMCs with Infanrix, a vaccine mix conferring protection against 
diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type B (HiB). We then measured 
the number of IL-17+ T-lymphocytes, so as to investigate the effect of IL1RL2 mutations on 
adaptive responses to bacterial and viral antigens. We found that the induction of T-cell mediated 
IL-17 production was comparable in individuals with knockout changes and control subjects 
(Fig. 6F). We obtained similar results when we stimulated PBMCs with C. albicans extracts, 
showing that the response to this fungal pathogen was also unaffected (Fig. 6F). Finally, we 
treated PBMCs with poly(I:C), a synthetic dsRNA which has been reported to up-regulate IL-
36, suggesting an involvement of IL-36 cytokines in anti-viral defenses (24). Again, we found 
that the induction of anti-viral (IFIT1, RSAD2) and anti-inflammatory gene products (IL-8) was 
comparable in control and knockout cells (Fig. 6, G and H). 
These observations demonstrate that normal immune function is largely preserved in the 
presence of IL1RL2 knockout mutations, suggesting that IL-36 blockade is likely to be well 
tolerated.    
 
Discussion  
In this study, we have investigated the IL-36 signaling pathway as a shared pathogenic 
driver for plaque and pustular psoriasis. We initially examined the genes that are up-regulated by 
IL-36 treatment in skin keratinocytes. This is the cell type where the expression of the IL-36 
receptor is highest and the effects of its stimulation are likely to be most pronounced. In fact, 
keratinocyte RNA sequencing allowed us to define a robust IL-36 signature, which is readily 
detectable among the genes that are over-expressed in psoriasis and those that map to disease 
susceptibility intervals. Our pathway enrichment analyses support a pathogenic model whereby 
IL-36 dependent genes drive several inter-connected feedback loops which potentiate IL-17 
signaling and leukocyte chemotaxis   
IL-36 is initially produced upon exposure to viral infection (24) and skin trauma, two 
well-known triggers of psoriasis exacerbation (3). IL-36 cytokines can then induce the 
expression of IL36G in an autocrine and paracrine fashion. Our real-time PCR and ELISA data 
indicate that this is a very robust up-regulation, which is likely to play an important role in the 
propagation of cutaneous inflammatory responses. Interestingly, the induction of IL36A and 
IL36B is much weaker (table S2). This suggests a prominence of IL-36γ in early disease 
pathogenesis that could potentially be exploited for targeted therapeutic intervention. 
IL-36 cytokines also drive the production of molecules that attract neutrophils (e.g. IL-8 
and CXCL1), dendritic cells (e.g. CCL20) and T lymphocytes (CXCL10 and CCL20) to sites of 
inflammation. The strongest effect was demonstrated for S100A7, a potent inducer of T-cell 
chemotaxis (25), which is up-regulated more than 100-fold by IL-36 and IL-36 The 
expression of LCN2, a molecule promoting neutrophil activation and infiltration (26), was also 
markedly increased by IL-36 treatment.  
In parallel, we showed that IL-36 can up-regulate the PLA2G4D phospholipase. This 
enzyme, repeatedly found to be over-expressed in psoriasis (27), generates lipid antigens for 
presentation to CD1a reactive T lymphocytes (12). Given that the activation of the latter cells 
results in the production of IL-17 and IL-22 (12), PLA2G4D induction is another mechanism 
whereby IL-36 potentiates TH17 activity. It is also possible that PLA2G4D might, like other 
molecules that are chronically over-expressed in psoriatic skin (28), be recognized as an auto-
antigen by HLA-restricted T cells.  
This in-silico derived pathogenic model is in keeping with the experimental 
characterization of IL-36 and PLA2G4D as psoriasis biomarkers (27, 29). It is also borne out by 
the results of our ex-vivo and in-vivo studies, where IL-36 blockers reduced IL-17 and IL-36 
expression in lesional skin, while also decreasing chemokine induction and T-cell infiltration.  
Importantly, the in-vivo work was carried out in a single animal model (albeit a widely 
used one), where IL-36 signaling inhibition could not completely reverse the consequences of 
imiquimod administration. While this is an important limitation, the anti-inflammatory effects of 
the treatment were supported by multiple experimental readouts and further validated by ex-vivo 
studies of patient skin, as recommended by the latest guidelines on the analysis of imiquimod-
induced dermatitis (15). In this context, the incomplete resolution of inflammation may simply 
reflect the short-term nature of the treatment (7 days for in-vivo and 24h for ex-vivo assays). 
Thus, the analysis of experimental systems enabling prolonged IL-36 blockade (e.g. 3D 
organotypic skin models) may be needed to fully validate the therapeutic potential of IL-36 
antagonists.    
Real-time PCR analysis of cells obtained from healthy donors showed that IL1RL2 levels 
were low in macrophages, dendritic cells and skin resident T lymphocytes. Although IL1RL2 
transcripts were clearly present in neutrophils, the significance of this observation is unclear, 
given that IL-36R surface expression is not detectable in these cells (30). Thus, the anti-
inflammatory effects of IL-36 blockade are likely mediated by a disruption of keratinocyte 
activation, resulting from the binding of IL-36Ra to an abundantly expressed receptor.  
Having demonstrated the in-vivo and ex-vivo efficacy of IL-36 signaling inhibition, we 
sought to investigate its long-term effects on human immune function. We undertook the 
phenotyping of individuals carrying IL1RL2 knockout mutations, as the analysis of loss-of-
function alleles can generate invaluable insights into the effects of targeted pharmaceutical 
inhibition. For instance, the safety of cholesterol-lowering PCSK9 inhibitors was supported by 
the observation that PCSK9 mutations do not affect human health (31).  
Here, we identified 12 individual harboring IL1RL2 knockout changes through an 
analysis of the Born in Bradford cohort (19). Although all the mutations present in this relatively 
small dataset were missense variants, pathogenicity predictions and IL-36 stimulations showed 
that these were deleterious alleles, which had a profound impact on receptor function. 
Conversely, clinical examinations did not uncover any evidence for impaired immune function. 
Serology tests also failed to detect any anomalies. Of particular interest, Aspergillus IgG 
levels were unremarkable, responses to C. albicans stimulation were normal, and none of the 
individuals with IL1RL2 knockout mutations presented with Candidiasis, even though IL-36 
signaling has been implicated in anti-fungal defenses (23). Although the size of our dataset does 
not allow us to exclude the possibility that IL-36 inhibition may confer vulnerability to rare 
infections, the data presented here indicates that IL-36 blockade is broadly compatible with 
normal immune function.  
Our observations have important translational implications. Although biologics targeting 
the IL-23/TH17 axis (especially IL-17 blockers) have transformed the treatment of psoriasis 
(32), disease management can still be problematic in real world settings, where the response to 
existing cytokine blockers does not match the efficacy levels observed in clinical trials (33). The 
efficiency of biologic therapies is even lower in pustular forms of psoriasis, where the need for 
an effective treatment is especially pressing (3). 
In this context, the findings obtained in our model systems support the development of 
IL-36 blockade as a therapeutic strategy for plaque and pustular psoriasis. While the phenotyping 
of individuals harboring IL1RL2 knockout mutations suggests a favorable safety profile for IL-36 
antagonists, we cannot exclude the possibility that these subjects may have developed 
compensatory immune mechanisms in early life. It is also possible that the effects of IL1RL2 
mutations may have been mitigated by genetic modifiers occurring at high frequency within the 
British Pakistani population. In spite of these limitations, the immune compromised phenotype of 
individuals suffering from other receptor deficiencies suggests that IL-36 signaling may indeed 
be dispensable to host defenses and warrants further characterization of IL-36 antagonists in 
Phase I clinical trials. 
 
Materials and Methods 
Study design 
The aim of this study was to demonstrate that IL-36 cytokines play a pathogenic role in 
psoriasis and to validate the IL-36 receptor as a therapeutic target. The first objective was 
pursued by demonstrating that IL-36 dependent genes identified in keratinocyte RNA-seq 
experiments are enriched in the psoriasis skin transcriptome and in disease associated loci. The 
second objective was investigated in in-vivo and ex-vivo studies of IL-36 receptor blockade. 
Deep phenotyping of individuals who lack a functional IL-36 receptor (IL-36R) owing to 
IL1RL2 knockout mutations, was also undertaken, in order to assess the long-term effects of IL-
36 signaling inhibition. 
The RNA-seq experiment was carried out in triplicate, to maximize the power of 
detecting differentially expressed genes at a coverage exceeding 2x107 reads per sample (34). In-
vivo studies were carried out in two groups of five mice, based on previous experience with 
comparable work (18). 
For the remaining experiments, sample sizes were dictated by the availability of psoriasis 
patients and IL1RL2 knockouts matching our strict inclusion criteria (see Supplementary 
Materials). mRNA levels, cytokine concentrations and leukocyte numbers were investigated as 
pre-defined end points. Immunofluorescence and ELISPOT images were quantified in a blinded 
fashion. No randomization of animal groups was necessary. Although drug administration to 
imiquimod-treated mice was not blinded, epidermal and scale thickness measurements were 
assessed in a blinded fashion. Primary data are located in table S10. 
Details of sampling and experimental replicates are provided in each figure legend. 
 
Human subjects 
This study was performed in accordance with the declaration of Helsinki and was 
approved by National Research Ethics Service Committee London - Chelsea. Written informed 
consent was obtained from all participants. Adult patients with psoriasis (n=10, table S8) were 
ascertained by dermatologists at Guy’s and St Thomas’ NHS Foundation Trust (see the 
Supplementary Materials for further details). Discarded skin was obtained from 4 healthy donors 
undergoing plastic surgery at Guy’s and St Thomas’ NHS Foundation Trust. Primary 
keratinocyte cultures were then established as described elsewhere (35). 
  
RNA sequencing 
Sequences were aligned to the Ensembl Human GRCh37 transcriptome using Bowtie 2-
2.2.2 (36) and the number of reads that mapped to each gene was quantified with htseq-count 
(37). 
Raw expression data for psoriatic skin, the IL-4 and IL-17 keratinocyte transcriptomes 
were downloaded from the Gene Expression Omnibus database (GSE67785, GSE59275 and 
GSE12109 respectively) and differential expression was computed using DESeq2 (38). Genes 
that were up-regulated by individual IL-36 cytokines (fold change ≥2, FDR <0.05) were selected 
for pathway enrichment analysis, which was implemented with Ingenuity Pathway Analysis 
(QIAGEN Bioinformatics).  
 
In-vivo IL-36 signaling blockade  
Mice were bred in the Francis Crick Institute animal facility under specified pathogen-
free conditions, where experiments were performed in accordance with institutional guidelines 
and UK Home Office regulations. Female BALB/cJ mice, 8 weeks old, treated for 5 consecutive 
days with 5% imiquimod (Meda AB) received daily intra-peritoneal injections (150 µg) of anti-
IL36R antibody (M616, Amgen) or rat IgG2a isotype control (Bio X Cell), starting on day -2 of 
imiquimod administration. Full thickness skin biopsies were collected on day 7 for histological 
staining, RNA extraction and flow-cytometry (see the Supplementary Materials for further 
details).  
 
Statistical analyses 
The significance of the overlap between the up-regulated genes (or enriched pathways) 
represented in Venn diagrams was calculated using the hyper-geometric distribution (phyper 
function in R). Fisher’s exact test was used to assess the enrichment of IL-36 signature genes 
within non-MHC intervals associated with psoriasis, schizophrenia and autism. The NHGRI-EBI 
Catalog of published genome-wide association studies (https://www.ebi.ac.uk/gwas, March 2017 
update) was queried using the search terms “psoriasis”, “schizophrenia” and “autism”, to 
generate three lists of disease associated single nucleotide polymorphisms (SNPs). A window of 
±50kb was added to the lead SNP at each locus and the genes mapping to the resulting regions 
were extracted using BioMart (http://www.ensembl.org/biomart).  
Fisher’s test and hyper-geometric distribution P values were adjusted for multiple testing 
using the Bonferroni correction. Unless otherwise indicated, experimental data are presented as 
means +/- SEM. Differences between groups were assessed using the unpaired Student's t test or 
one-way ANOVA with Dunnett's post-test, as appropriate.   
 
Supplementary Materials 
Materials and Methods 
Fig. S1. IL-4 target genes are an appropriate negative control for IL-36 enrichment analyses, as 
there is no overlap between IL-4 and IL-36 signature genes. 
Fig. S2. The pathways that underlie the pathogenesis of GPP are enriched within the IL-36 
transcriptome. 
Fig. S3. Mechanical trauma up-regulates IL-36 production by cultured keratinocytes.  
Fig. S4. Proposed pathogenic model illustrating the role of IL-36 as an amplifier of TH17 
signaling in psoriasis.  
Fig. S5. In vivo IL-36 signaling blockade reduces the infiltration of IL-17 producing αβ T-cells in 
imiquimod-induced psoriasiform dermatitis. 
Fig. S6. The genes encoding the IL-36 receptor subunits are expressed in PBMCs. 
Fig. S7. Dose and time dependent effects of IL-36 cytokines in primary keratinocytes. 
Fig. S8. Complete western blots for figure 5E. 
Table S1. RNA-seq coverage statistics. 
Table S2. Keratinocyte genes that are up- or down-regulated by IL-36 treatment. 
Table S3: Overlap between the IL36_182 set and keratinocyte genes up-regulated by IL-17.   
Table S4. Results of pathway enrichment analysis. 
Table S5. Rare homozygous IL1RL2 variants observed in the Born in Bradford cohort. 
Table S6. Full blood counts of individuals with homozygous IL1RL2 mutations and controls. 
Table S7. Immune serology results.  
Table S8. Skin donor demographics. 
Table S9. Oligonucleotide primers used in the study. 
Table S10. Raw data for in-vivo and ex-vivo experiments. 
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 Figure Legends 
Fig. 1. Identification of IL-36 signature genes in human keratinocytes. (A) Principal 
Component Analysis of RNA-seq data from IL-36 treated and untreated keratinocytes. Each dot 
represents an experimental replicate. (B) Heatmap generated from unsupervised clustering of 
differentially expressed genes (FDR<0.05) transcript levels. (C) Volcano plots show the genes 
that are most strongly induced by IL-36 treatment. Black dots refer to genes showing a log2|fold 
change| > 1. Labels indicate the ten most significantly up-regulated genes in each dataset (black 
font) and the loci selected for real-time PCR validation (red font). The Venn diagram displays 
the intersection of up-regulated genes (FDR<0.05, fold change ≥ 2) across the IL-36α, -β and - 
transcriptomes. The number of up-regulated genes for each dataset is reported in parentheses. 
(D) The Venn diagrams show the intersection of the core IL-36 transcriptome (IL36_182 set) 
with the genes over-expressed in GPP or psoriasis (Ps) skin lesions. The 10 IL-36 signature 
genes that are most significantly up-regulated in the psoriasis and GPP datasets are listed beside 
each diagram. (E) Bar chart showing the over-representation of the IL36_182 set among genes 
lying within psoriasis susceptibility regions detected in GWAS. Schizophrenia and autism 
susceptibility intervals were analyzed as negative controls. 
Fig. 2. The pathways that underlie the pathogenesis of psoriasis are enriched within the IL-
36 transcriptome. (A) Pathways displaying the most significant enrichment in the IL-36α, -β 
and - transcriptomes. The red dotted line shows the –log(FDR) level corresponding to an 
FDR<0.05. (B) The Venn diagram shows the intersection of the pathways that are enriched 
(FDR<0.05) in the three IL-36 transcriptomes. The number of enriched pathways for each 
dataset is reported in parentheses. (C) The Venn diagram shows the intersection of the pathways 
that are enriched in psoriasis (Ps) and in the three IL-36 transcriptomes. The 10 most 
significantly enriched pathways are reported on the right. 
Fig. 3. IL-36 cytokines amplify immune responses implicated in psoriasis pathogenesis. (A) 
Validation of IL-36 responsiveness in genes that contribute to the pathogenesis of psoriasis. 
Primary keratinocytes from 3 independent healthy donors were treated with IL-36α, -β, –γ or 
vehicle (-). Gene expression was compared in treated vs. untreated keratinocytes, using real-time 
PCR. Data for each individual donor was normalized to transcript levels in untreated cells and is 
presented as the mean +/- standard error of the mean (SEM) of measurements obtained in 
triplicate stimulations. (B) Effect of IL-36 cytokines on the secretion of IL-36γ by keratinocytes. 
IL-36γ release was quantified by ELISA following stimulation of primary keratinocytes with IL-
36α, -β, –γ. Data for each individual donor are presented as the mean +/- SEM. P values were 
calculated by Student’s t-test. *P < 0.05, **P < 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
Fig. 4. In-vivo IL-36 signaling blockade ameliorates imiquimod-induced psoriasiform 
dermatitis. Mice received an anti-IL36R or isotype-matched control antibody (n=5 per group) 
for 7 days, starting 2 days prior imiquimod treatment. The experiment was carried out twice with 
comparable results. (A) Representative photographs (left) and haematoxylin/eosin staining 
(centre) of imiquimod-treated mice receiving either anti-IL36R or an isotype antibody. Untreated 
skin is shown as a reference. Measurements of epidermis and scale thickness are plotted on the 
right. Scale bar: 100µm. (B) Real-time PCR analysis of skin differentiation (Krt10) and 
hyperproliferation (Krt16) markers, in imiquimod-treated mice receiving either an isotype 
antibody or anti-IL-36R. (C) Quantification of neutrophils infiltrating the skin of untreated vs. 
imiquimod-treated mice receiving either an isotype antibody or anti-IL-36R. Representative 
FACS plots of CD11b+Ly6G+ neutrophils gated within live CD45+ cells are also shown. (D) 
Quantification of dermal  T-cells infiltrating the skin of untreated vs. imiquimod-treated mice 
receiving either an isotype antibody or anti-IL-36R. (E) Representative FACS plot (left) and 
quantification (right) of IL-17 and IL-22 producing dermal  T-cells gated within live CD45+ 
cells in the skin of untreated vs. imiquimod-treated mice receiving either an isotype antibody or 
anti-IL-36R. (F) Real-time PCR of genes encoding chemokines and cytokines relevant to 
psoriasis in untreated vs. imiquimod-treated mice receiving either an isotype antibody or anti-IL-
36R. All data were normalized to the transcript levels observed in untreated mice and are 
presented as means +/- SEM. P values were calculated with one-way ANOVA and Dunnett’s 
post-test. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 
Fig. 5. Ex-vivo IL-36 receptor blockade reduces inflammation in psoriasis skin lesions. (A 
and B) Lesional (LS) skin biopsies were cultured for 24h in the presence or absence of IL-36Ra. 
For each patient, a paired non-lesional (NL) sample was analyzed as a reference. Cytokine 
expression was assessed by real-time PCR (A) (n=5 patients, each represented by one line per 
graph), while IL-17 and IL-36 release was quantified by ELISA (B) (n=3 patients, data presented 
as mean +/- SEM). All P values were calculated by one-way Repeated Measures ANOVA with 
Greenhouse-Geisser correction. (C) Representative confocal microscopy images of CD3+ T-cells 
and CD11c+ dendritic cells in lesional skin samples treated with IL-36Ra (n=3) (left). The 
number of positive cells per field, quantified in ≥ 5 images per sample, is presented as mean +/- 
SEM (right). P values were calculated by one-way ANOVA followed by Dunnett’s post-test. *P 
< 0.05, **P < 0.01, ****P ≤ 0.0001. Scale bar: 50µm. The dermal-epidermal junction is 
highlighted by a dotted line. (D) Real-time PCR of IL1RL2 expression in disease relevant cell 
types. Each bar shows the median and range of expression values in 2-5 healthy donors. (E) 
Western blotting (left, loading control: hsc70) and densitometric analysis of p-p38/p38 ratios 
(right) after IL-36Ra treatment of lesional skin. The data are representative of results from 2 
independent skin samples.  
Fig. 6. Individuals with homozygous IL1RL2 mutations show no signs of abnormal immune 
function. (A) Demographics and mutation status of the Born in Bradford participants analyzed in 
the study. Bold font denotes individuals recalled for further phenotyping. (B) Representative 
chromatograms confirming the genotypes of recalled subjects. The nucleotide changes are 
highlighted by red asterisks. (C and D) PBMCs obtained from individuals with IL1RL2 knockout 
mutations (n=6) and control (n=4) subjects were treated  for 7h with IL-36α. Cytokine 
production was determined by real-time PCR (C, data presented as the mean of triplicate 
stimulations) and ELISA (D, data presented as the mean of duplicate stimulations). (E to H) 
PBMCs obtained from individuals with IL1RL2 knockout mutations and control subjects were 
treated with PMA/Ionomycin (E), Infanrix 5-in-1 vaccine (F), Candida albicans extracts (F) or 
poly(I:C) (G and H). Gene expression was measured by real-time PCR (E and G, data presented 
as the mean of triplicate stimulations), numbers of IL-17-secreting T cells were quantified by 
ELISPOT (F, data presented as the mean stimulation index observed in triplicate stimulations; 
example photomicrographs are shown) and cytokine release was determined by ELISA (H, data 
presented as the mean of duplicate stimulations). All P values were calculated by Student’s t-test. 
**P < 0.01; ns, not significant. KMutH, knockout mutation homozygotes; Ctr, controls.  
 
